Literature DB >> 22169936

Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.

James Robert Brašić1, Nicola Cascella, Anil Kumar, Yun Zhou, John Hilton, Vanessa Raymont, Andrew Crabb, Maria Rita Guevara, Andrew G Horti, Dean Foster Wong.   

Abstract

Utilizing postmortem data (Breese et al. [2000] Neuropsychopharmacology 23:351-364), we hypothesized that the densities of high-affinity neuronal α4β2 nicotinic acetylcholine receptors (nAChRs) in the brain exist in a continuum from highest to lowest as follows: smokers without schizophrenia > smokers with schizophrenia > nonsmokers without schizophrenia > nonsmokers with schizophrenia. Application of the Kruskal-Wallis Test (Statacorp, 2003) to the postmortem data (Breese et al. [2000] Neuropsychopharmacology 23:351-364) confirmed the hypothesized order in the cortex and the hippocampus and attained significance in the caudate and the thalamus. Positron emission tomography (PET) was performed for 60 min at 6 h after the intravenous administration of 444 megabequerels [MBq] (12 mCi) 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA), a radiotracer for high-affinity neuronal α4β2 nAChRs, as a bolus plus continuous infusion to 10 adults (seven men and three women) (six smokers including five with paranoid schizophrenia and four nonsmokers) ranging in age from 22 to 56 years (mean 40.1, standard deviation 13.6). The thalamic nondisplaceable binding potential (BP(ND) ) was 1.32 ± 0.19 (mean ± standard deviation) for healthy control nonsmokers; 0.50 ± 0.19 for smokers with paranoid schizophrenia; and 0.51 for the single smoker without paranoid schizophrenia. The thalamic BP(ND) s of nonsmokers were significantly higher than those of smokers who smoked cigarettes a few hours before the scans (P = 0.0105) (StataCorp, 2003), which was likely due to occupancy of nAChRs by inhaled nicotine in smokers. Further research is needed to rule out the effects of confounding variables.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169936      PMCID: PMC3445266          DOI: 10.1002/syn.21520

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  48 in total

1.  Smoking and schizophrenia: abnormal nicotinic receptor expression.

Authors:  S Leonard; C Breese; C Adams; K Benhammou; J Gault; K Stevens; M Lee; L Adler; A Olincy; R Ross; R Freedman
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

2.  Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.

Authors:  D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

3.  Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.

Authors:  C R Breese; M J Lee; C E Adams; B Sullivan; J Logel; K M Gillen; M J Marks; A C Collins; S Leonard
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

4.  Decreased vesicular acetylcholine transporter and alpha(4)beta(2) nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning.

Authors:  Mitchell Quinlivan; Sylvie Chalon; Jackie Vergote; Jasmine Henderson; Andrew Katsifis; Michael Kassiou; Denis Guilloteau
Journal:  Neurosci Lett       Date:  2007-03-06       Impact factor: 3.046

5.  Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.

Authors:  Kai Kendziorra; Henrike Wolf; Philipp Mael Meyer; Henryk Barthel; Swen Hesse; Georg Alexander Becker; Julia Luthardt; Andreas Schildan; Marianne Patt; Dietlind Sorger; Anita Seese; Herman-Josef Gertz; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

6.  The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder.

Authors:  M F Ward; P H Wender; F W Reimherr
Journal:  Am J Psychiatry       Date:  1993-06       Impact factor: 18.112

Review 7.  Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.

Authors:  Rajiv Tandon; Matcheri S Keshavan; Henry A Nasrallah
Journal:  Schizophr Res       Date:  2008-06-02       Impact factor: 4.939

8.  Synthesis procedure for routine production of 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]F-A-85380).

Authors:  Andreas Schildan; Marianne Patt; Osama Sabri
Journal:  Appl Radiat Isot       Date:  2007-03-12       Impact factor: 1.513

9.  Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors.

Authors:  Andrew G Horti; Dean F Wong
Journal:  PET Clin       Date:  2009-01-01

Review 10.  Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography.

Authors:  Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Robert F Dannals
Journal:  Life Sci       Date:  2009-03-18       Impact factor: 5.037

View more
  10 in total

Review 1.  Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease.

Authors:  Kazuyuki Takata; Hiroyuki Kimura; Daijiro Yanagisawa; Koki Harada; Kaneyasu Nishimura; Yoshihisa Kitamura; Shun Shimohama; Ikuo Tooyama
Journal:  Molecules       Date:  2022-04-27       Impact factor: 4.927

Review 2.  Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors.

Authors:  Alina Kassenbrock; Neil Vasdev; Steven H Liang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 3.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939

Review 4.  Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Authors:  Douglas L Boggs; Jon Carlson; Jose Cortes-Briones; John H Krystal; D Cyril D'Souza
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Evaluation of [18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice.

Authors:  Cristian C Constantinescu; Adriana Garcia; M Reza Mirbolooki; Min-Liang Pan; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2012-12-21       Impact factor: 2.408

6.  The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.

Authors:  Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2013-02-22

Review 7.  Molecular substrates of schizophrenia: homeostatic signaling to connectivity.

Authors:  M A Landek-Salgado; T E Faust; A Sawa
Journal:  Mol Psychiatry       Date:  2015-09-22       Impact factor: 15.992

8.  Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results.

Authors:  Mathias Kranz; Bernhard Sattler; Solveig Tiepolt; Stephan Wilke; Winnie Deuther-Conrad; Cornelius K Donat; Steffen Fischer; Marianne Patt; Andreas Schildan; Jörg Patt; René Smits; Alexander Hoepping; Jörg Steinbach; Osama Sabri; Peter Brust
Journal:  EJNMMI Phys       Date:  2016-10-21

9.  Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome.

Authors:  James R Brašić; Ayon Nandi; David S Russell; Danna Jennings; Olivier Barret; Anil Mathur; Keith Slifer; Thomas Sedlak; Samuel D Martin; Zabecca Brinson; Pankhuri Vyas; John P Seibyl; Elizabeth M Berry-Kravis; Dean F Wong; Dejan B Budimirovic
Journal:  Brain Sci       Date:  2020-11-24

10.  The Yin and Yang of Nicotine: Harmful during Development, Beneficial in Adult Patient Populations.

Authors:  Danielle S Counotte; August B Smit; Sabine Spijker
Journal:  Front Pharmacol       Date:  2012-10-08       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.